Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

William J Gradishar,Rashmi Kumar,P Kelly Marcom,John H Ward,Joanne Mortimer,Jairam Krishnamurthy,Mary Lou Smith,Steven J Isakoff,Meena S Moran,Rebecca Aft,Melinda L Telli,Harold J Burstein,Sharon H Giordano,Matthew P Goetz,Sameer A Patel,Benjamin O Anderson,Ingrid A Mayer,Jennifer L Burns,Kimberly H Allison,Jame Abraham,Sarah L Blair,Hope S Rugo,Hatem Soliman,Lori J Goldstein,Lori J Pierce,Doreen M Agnese ,Chau T Dang ,Erica Stringer-Reasor ,Karen L Smith ,Ruth O’regan ,Joseph C Young ,Janice A Lyons ,Amy M Sitapati ,Jennifer M Matro ,Anthony Elias

doi:10.6004/jnccn.2020.0016

Abstract

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

Full Text